Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-A1904 in CLDN18.2-positive advanced solid tumors
NCT06350006Phase 1Recruiting
- Sponsor
- Hengrui Therapeutics
- Start
- May 2024
- Primary completion
- Dec 2027
- Modality
- Small Molecules, Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of garetatug rezetecan in solid tumor (advanced stage) (2 arms), sponsored by Hengrui Therapeutics. Primary endpoints: Adverse Events at 24 months, Dose Limiting Toxicity at 24 months and 3 more. Started May 2024; status: recruiting.
02
Drugs
garetatug rezetecan
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT06350006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06350006.